Lilly(Eli) & Company (LLY) Valuation

Based on the GoodMoat Investment Framework, Eli Lilly's valuation assessment presents a mixed picture. The current price of $909.98 is below the GoodMoat Target of $1,015.63, implying a margin of safety of approximately 10.4%. According to the framework's bands, a 10–20% MoS is considered 'Marginal,' falling short of the 20% threshold typically sought for a 'Favourable' valuation. The primary valuation multiple, a P/E of 42.0, is exceptionally high. This far exceeds the typical sector average for large-cap pharmaceuticals and is likely at the high end of the stock's own historical range, indicating the market is pricing in tremendous future growth. Supporting this, the Free Cash Flow Yield is a low 1.0%, suggesting the stock is expensive on a cash flow basis. While the company's quality is undeniable—evidenced by a 42.6% YoY revenue growth, a 77.8% ROE, and a 40.4% operating margin—the valuation multiples demand that this stellar performance continues unabated. For a value investor, the price offers only a marginal discount to estimated fair value and requires high confidence that current growth rates are sustainable to justify the premium.